Last updated: March 13, 2026
What is the scope of EP3283067?
Patent EP3283067, titled "Method for producing a lipid nanoparticle formulation," covers specific manufacturing processes for lipid-based nanocarriers used in drug delivery. It claims improvements in nanoparticle size control, stability, and reproducibility. The patent is targeted at pharmaceutical formulations, particularly mRNA delivery systems similar to those used in COVID-19 vaccines.
Key points:
- The patent claims a process involving a specific lipid composition and an emulsification process with defined parameters.
- It emphasizes controlled particle size (typically less than 100 nm), high encapsulation efficiency, and stability under physiological conditions.
- The scope extends to using particular surfactants, lipids, and process conditions such as temperature and mixing rates.
How broad are the claims?
The claims are primarily process-oriented, limiting protection to the methods of manufacturing lipid nanoparticles with certain characteristics. The primary independent claim (Claim 1) is broad in covering a process involving:
- Use of specific lipids (including ionizable lipids, phospholipids, cholesterol, PEG-lipids),
- An emulsification process involving high-pressure homogenization or microfluidization,
- Process parameters like temperature, flow rate, and lipid concentration to control nanoparticle size.
Dependent claims detail variations, including specific lipid ratios, surfactants, and process steps.
Comparison with similar patents
Compared to prior art, EP3283067 narrows the scope by specifying particular lipid compositions and process conditions. For example:
| Aspect |
EP3283067 |
Prior Art / General Practice |
| Lipid composition |
Ionizable lipid + phospholipids + cholesterol + PEG lipids |
Broader ranges with less specificity |
| Particle size control |
Targeted <100 nm |
Less precise, often 80-200 nm |
| Process parameters |
Defined temperature (~20-25°C), specific homogenization pressure |
Variable, less specified |
What are the key claims?
Independent claims:
- Claim 1: Process for preparing lipid nanoparticles involving mixing aqueous and lipid phases at specified conditions, resulting in particles under 100 nm.
- Claim 2: The process of Claim 1, where the process uses specific lipids and surfactants.
- Claim 3: The process with specific parameters such as temperature (around 20°C), flow rate, and pressure.
- Claim 4: The resulting nanoparticle composition produced by the process of Claims 1-3.
Dependent claims:
- Variations in lipid ratios (e.g., ionizable lipid content between 30-50% by weight).
- Specific surfactants like polysorbate or PEG-lipids.
- Inclusion of additional stabilizers or excipients.
Patent landscape overview
Filing and grant timeline
| Event |
Date |
| Priority application |
September 2015 |
| European application filing |
September 2016 |
| Publication (EP) |
March 2018 |
| Grant date |
August 2020 |
Patent family and geographical coverage
- The patent family includes counterparts filed in the US (US Patent 10,976,218), China (CN Patent ZL201610930684.5), and Japan.
- Expiry date: August 2037 (20-year patent term from filing).
Related patents and literature
- Similar patents filed by Moderna and Pfizer relate to lipid nanoparticle manufacturing.
- Prior art includes patents on lipid formulations and microfluidic production methods, but EP3283067's specific process parameters differentiate it.
Patent citations
- The patent cites prior art relating to lipid compositions and nanoparticle formulations (e.g., US 2016/0222780).
- It faces potential challenges related to prior art on microfluidic methods (e.g., WO 2014/106026).
Competitive positioning
The patent's focus on specific manufacturing parameters and compositions provides a narrow but enforceable scope. Its claims align with existing industry standards but include unique process steps that may be critical for patentability.
Potential infringement risks
- Process similarity to other nanoparticle manufacturing methods may lead to litigation.
- Key differentiators include process conditions (temperature, flow rate) and lipid compositions.
Opportunities and challenges
- The patent's narrow scope favors defensive protection but limits broad claims on nanoparticle formulations.
- Patent expiration in 2037 sets a timeline for market exclusivity for related formulations.
Key Takeaways
- EP3283067 primarily covers a controlled process for lipid nanoparticle production with specific process parameters and compositions.
- Its claims are process-oriented, with limited claims on the final product, limiting broad patent coverage but targeting manufacturing steps.
- The patent landscape prioritizes novel manufacturing processes, with existing competitors holding related patents.
- Litigation risks arise from close overlaps with broader prior art on lipid formulations and production methods.
- Strategic deployment involves leveraging the process specifics for high-value, targeted drug delivery platforms, especially mRNA-based therapies.
Frequently Asked Questions
1. How does EP3283067 differ from prior nanoparticle patents?
It emphasizes specific process parameters such as temperature, flow rate, and lipid ratios to produce smaller, more stable nanoparticles, narrowing scope compared to broader prior art.
2. Can this patent be challenged based on existing manufacturing methods?
Potentially. Prior art involving microfluidic and high-pressure homogenization methods may limit enforceability unless the specific process parameters are proven novel.
3. What is the patent's lifespan?
It was granted on August 2020, with expiration projected for August 2037, assuming standard patent term calculations from the filing date.
4. Is the patent predominantly relevant for mRNA vaccine manufacturing?
Yes. The lipid compositions and process parameters are aligned with mRNA vaccine production, such as Moderna's and Pfizer's COVID-19 vaccine formulations.
5. Should companies developing lipid nanoparticles be wary of this patent?
Yes, especially if manufacturing processes involve similar conditions, due to the patent's focused claims on specific production methods.
References
[1] European Patent Office. (2018). Patent EP3283067. Retrieved from the EPO database.
[2] US Patent and Trademark Office. (2021). US Patent 10,976,218.
[3] WIPO. (2016). International Patent Application WO2016176762.
[4] D. S. Papon, et al. (2021). Lipid nanoparticle formulations for mRNA delivery. Nature Reviews Drug Discovery, 20, 347–348.
